Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
SAGE Therapeutics ( (SAGE) ) has shared an announcement.
On June 11, 2025, Sage Therapeutics held its Annual Meeting of Stockholders where key decisions were made, including the approval of an amendment to the 2014 Employee Stock Purchase Plan to increase authorized shares by 500,000. The meeting also saw the election of two Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent accounting firm, and approval of executive compensation, reflecting strategic moves to strengthen governance and financial oversight.
The most recent analyst rating on (SAGE) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on SAGE Therapeutics stock, see the SAGE Stock Forecast page.
Spark’s Take on SAGE Stock
According to Spark, TipRanks’ AI Analyst, SAGE is a Neutral.
The overall stock score for SAGE Therapeutics is primarily influenced by significant financial challenges, including declining revenues and negative cash flows, leading to a low financial performance score. Technical analysis also points to a bearish trend. While the earnings call provided some positive developments, it was not enough to offset the broader financial concerns.
To see Spark’s full report on SAGE stock, click here.
More about SAGE Therapeutics
Sage Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines to treat central nervous system disorders.
Average Trading Volume: 973,157
Technical Sentiment Signal: Strong Sell
Current Market Cap: $423.9M
For an in-depth examination of SAGE stock, go to TipRanks’ Overview page.